Relapsed or Refractory Lymphoid Malignancies

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Mereo BioPharma
Mereo BioPharmaUK - London
1 program
1
OMP-52M51Phase 11 trial
Active Trials
NCT01703572CompletedEst. Jan 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mereo BioPharmaOMP-52M51

Clinical Trials (1)

A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Start: Oct 2012Est. completion: Jan 2016
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space